Investors

Events and Presentations

Analyst Coverage

Corporate Governance

Investor Contacts & Alerts

News Releases

Month Year

Month Year

Jan 23, 2018

Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

STI Trial Investigates Amphora for Prevention of Urogenital Chlamydia Trachomatis Infection in Women
Jan 17, 2018

Evofem Announces Closing Of Merger With Neothetics

Commences Trading on NASDAQ Capital Market on Thursday, January 18, 2018 Under Ticker Symbol "EVFM"
Nov 16, 2017

Form S-4 Filed with SEC
Oct 17, 2017

Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company
Jul 27, 2017

Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) for Prevention of Pregnancy
Jun 29, 2017

AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
Dec 16, 2016

Evofem Biosciences Appoints Dr. David Friend as Chief Scientific Officer
Aug 29, 2016

Evofem Biosciences Appoints Russell Barrans as Chief Commercial Officer
Aug 17, 2016

Evofem Biosciences Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH
Aug 4, 2016

Evofem secures $25 million in Series D funding

EVOFEM SECURES $25.0 MILLION IN SERIES D FUNDING

Show per page